INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) announced Monday that its
MONARCH 2 breast cancer Study trial of abemaciclib met the primary endpoint of
progression-free survival. Abemaciclib, in combination with fulvestrant, was
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) announced Saturday that
patients with moderate-to-severe plaque psoriasis treated with Taltz
(ixekizumab) demonstrated superior efficacy at 24 weeks compared to patients
treated with Stelara...